PepVault
/ database / Monoamine Reuptake Inhibitor

Tesofensine

Also: NS2330

Non-peptide oral weight-loss agent with strong Phase 2 data.

Evidence
emerging
Legal status
research only
Half-life
~9 days
Routes
oral
View on Limitless LifeAdd to compare
What it is

Tesofensine is not a peptide but is widely discussed alongside them. Phase 2 data showed weight loss roughly double that of conventional agents at the time, but cardiovascular concerns slowed development.

Mechanism

Triple reuptake inhibitor of noradrenaline, dopamine and serotonin.

Outcomes it's matched to
Safety

Blood pressure and heart rate increases; insomnia; mood effects.

  • Cardiovascular disease
  • Anxiety disorders
Legal context

Approved in Mexico (Tesomet). Not approved in US/EU.

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault